Lupus & antiphospholipid syndrome
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study
Authors' conclusion
Inactivated SARS-CoV-2 vaccine does not influence the profile of anti-phospholipid antibodies and anti-PF4-heparin antibodies nor induces thrombotic events in primary APS patients.
Study context
- Population
- Primary APS patients receiving two doses of inactivated SARS-CoV-2 vaccine voluntarily
- Participants
- 39 patients
- Exposure
- Before vs 4 weeks after the second dose of inactivated SARS-CoV-2 vaccine (BBIBPCorV)
- Pre-vaccinationn = 39reference
- Post-vaccinationn = 39
- Outcome
- Presence of prothrombotic autoantibodies (aPL, aPF4-heparin, ANA) and thrombotic events
- Follow-up
- 4 weeks after the second dose
Methodological detailssingle-group, before–after
- Single-group, before–after
Main finding
As reported in the abstract
Presence of 11 autoantibodies, before vs after vaccination (n) · 4 weeks after second dose
- No significant difference in the presence of all 11 autoantibodies
- Before vaccination vs After vaccination: P = 0.64
- Before vaccination vs After vaccination: P = 0.34
- Before vaccination vs After vaccination: P = 0.64
- Before vaccination vs After vaccination: P = 1.00
- Before vaccination vs After vaccination: P = 0.36
- Before vaccination vs After vaccination: P = 0.69
- Before vaccination vs After vaccination: P = 0.48
- Before vaccination vs After vaccination: P = 0.26
- Before vaccination vs After vaccination: P = 0.16
- Before vaccination vs After vaccination: P = 1.00
- Before vaccination vs After vaccination: P = 0.48
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| aPL risk profile distributionBefore vaccination vs After vaccination | P = 0.799 |
| aPL risk profile distributionBefore vaccination vs After vaccination | P = 0.799 |
aPL risk profile distribution
- Distribution of aPL profile not affected by vaccination
Treatment regimens
- No adjustment to ongoing treatment after vaccination
Safety
Thrombotic disorder · minimum follow-up 12 weeks
- No case exhibited symptoms of thrombotic disorder
Original publication
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study. Rheumatology (Oxford). Published 22 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →